1
OP2C : Prialt® Observatory in Clinical Practice
Condition(s):Refractory PainLast Updated:September 30, 2022Recruiting
Ziconotide as an Intervention: 11 Clinical Trials, Page 1 of 2
Hide Studies Not Open or Pending
2
Intrathecal Bolus Doses of Ziconotide
Condition(s):Peripheral NeuropathyLast Updated:December 30, 2014Completed
3
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
Condition(s):Painful Myelopathy; Painful NeuropathyLast Updated:September 18, 2018Withdrawn
4
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
Condition(s):Pain; Neuropathic Pain; Intractable Pain; CancerLast Updated:March 24, 2023Active, not recruiting
5
Patient Registry of Intrathecal Ziconotide Management(PRIZM)
Condition(s):Patients With Severe Chronic PainLast Updated:March 16, 2017Completed
6
Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain
Condition(s):PainLast Updated:December 14, 2015Completed
7
Prialt (Ziconotide) In Severe Chronic Pain
Condition(s):PainLast Updated:December 14, 2015Completed
8
Ziconotide as First-Line IDT
Condition(s):Neuropathic PainLast Updated:January 12, 2021Completed
9
A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain
Condition(s):HIV Infections; Cancer; PainLast Updated:June 24, 2005Completed
10
Intrathecal Ziconotide Antalgic Efficacy for Severe Refractory Neuropathic
Condition(s):Severe Refractory Neuropathic Pain; Spinal Cord LesionsLast Updated:May 8, 2019Unknown status